Wedbush Securities’s Adicet Bio ACET Stock Holding History

Wedbush Securities’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-230	Closed	-$236K	–	900
2018 Q2	$236K	Buy	+230	New	+$248K	0.03%	661

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wedbush Securities's ACET Position: Q3 2018 in Review

Wedbush Securities sold out of Adicet Bio (ACET) in Q3 2018, closing a stake of 230 shares — an estimated $236K sold.

Wedbush Securities first reported a position in ACET in Q2 2018 and held it in 1 quarter. The position peaked at $236K in Q2 2018. 40 funds tracked by Wall St. Rank hold ACET as of Q3 2018.

Wedbush Securities reported no remaining Adicet Bio position as of Q3 2018 after selling out during the quarter.
Wedbush Securities sold 230 Adicet Bio shares in Q3 2018, an estimated $236K.
Wedbush Securities first reported a position in Adicet Bio in Q2 2018 and held it in 1 quarter.
Wedbush Securities's Adicet Bio position peaked at $236K in Q2 2018.
40 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2018.

Based on Wedbush Securities's 13F filing for Q3 2018, filed 13 Nov 2018.